First test of new drug duo aims to shrink breast tumors before surgery
NCT ID NCT04481113
Summary
This early-stage study tested the safety and best dose of two oral drugs, abemaciclib and niraparib, given together before surgery for certain types of breast cancer. The goal was to see if this combination could shrink tumors effectively with manageable side effects. The study involved a small group of 8 participants with hormone receptor-positive, HER2-negative breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.